0001834376--06-302022Q2false0013551651313551651317000000450000000.33330001834376innv:AdventistHealthSystemWestJointVentureMember2021-02-090001834376innv:Sh1Member2021-07-012021-12-310001834376innv:PwdMember2021-12-310001834376us-gaap:TreasuryStockMember2020-07-012020-12-310001834376innv:EquityIncentivePlan2016Member2020-07-270001834376innv:ThirdAmendedAndRestatedCreditAgreementMember2020-07-272020-07-270001834376innv:TwoThousandSixteenIncentivePlanMemberinnv:OptionCancelationAgreementMember2020-07-272020-07-270001834376us-gaap:RetainedEarningsMember2021-12-310001834376us-gaap:NoncontrollingInterestMember2021-12-310001834376us-gaap:AdditionalPaidInCapitalMember2021-12-310001834376us-gaap:RetainedEarningsMember2021-09-300001834376us-gaap:NoncontrollingInterestMember2021-09-300001834376us-gaap:AdditionalPaidInCapitalMember2021-09-300001834376srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2021-06-300001834376srt:ScenarioPreviouslyReportedMemberus-gaap:NoncontrollingInterestMember2021-06-300001834376srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember2021-06-300001834376srt:RestatementAdjustmentMemberus-gaap:NoncontrollingInterestMember2021-06-300001834376us-gaap:RetainedEarningsMember2021-06-300001834376us-gaap:NoncontrollingInterestMember2021-06-300001834376us-gaap:AdditionalPaidInCapitalMember2021-06-300001834376us-gaap:RetainedEarningsMember2020-12-310001834376us-gaap:NoncontrollingInterestMember2020-12-310001834376us-gaap:AdditionalPaidInCapitalMember2020-12-310001834376us-gaap:RetainedEarningsMember2020-09-300001834376us-gaap:NoncontrollingInterestMember2020-09-300001834376us-gaap:AdditionalPaidInCapitalMember2020-09-3000018343762020-09-300001834376us-gaap:RetainedEarningsMember2020-06-300001834376us-gaap:NoncontrollingInterestMember2020-06-300001834376us-gaap:AdditionalPaidInCapitalMember2020-06-300001834376us-gaap:CommonStockMember2021-12-310001834376us-gaap:CommonStockMember2021-09-300001834376us-gaap:CommonStockMember2021-06-300001834376us-gaap:TreasuryStockMember2020-12-310001834376us-gaap:CommonStockMember2020-12-310001834376us-gaap:TreasuryStockMember2020-09-300001834376us-gaap:CommonStockMember2020-09-300001834376us-gaap:TreasuryStockMember2020-06-300001834376us-gaap:CommonStockMember2020-06-300001834376innv:EquityIncentivePlan2016Member2021-07-012021-12-310001834376innv:EquityIncentivePlan2016Member2020-07-272020-07-270001834376innv:OmnibusIncentivePlan2021Member2021-12-310001834376innv:EquityIncentivePlan2020Member2021-12-310001834376innv:EquityIncentivePlan2016Member2021-12-310001834376srt:MinimumMemberinnv:TimeVestingAwardsMember2021-07-012021-12-310001834376innv:PerformanceBasedRestrictedStockUnitsMemberinnv:OmnibusIncentivePlan2021Member2021-12-310001834376innv:TimeBasedRestrictedStockUnitsMemberinnv:OmnibusIncentivePlan2021Member2021-06-300001834376innv:TimeVestingUnitsProfitInterestsMember2021-06-300001834376innv:PerformanceVestingUnitsProfitInterestsMember2021-06-300001834376innv:PerformanceBasedRestrictedStockUnitsMemberinnv:OmnibusIncentivePlan2021Member2021-07-012021-12-310001834376innv:EquityIncentivePlan2020Member2021-07-012021-12-310001834376innv:PerformanceVestingUnitsProfitInterestsMember2021-07-012021-12-310001834376innv:OmnibusIncentivePlan2021Member2021-07-012021-12-310001834376innv:OptionCancelationAgreementMember2020-07-272020-07-270001834376innv:TimeBasedOptionAwardMember2021-07-012021-12-310001834376innv:OtherServiceRevenueMember2021-10-012021-12-310001834376innv:CapitationRevenueMember2021-10-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMemberus-gaap:AllOtherSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:CapitationRevenueMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:CapitationRevenueMember2021-07-012021-12-310001834376innv:OtherServiceRevenueMember2021-07-012021-12-310001834376innv:CapitationRevenueMember2021-07-012021-12-310001834376innv:OtherServiceRevenueMember2020-10-012020-12-310001834376innv:CapitationRevenueMember2020-10-012020-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMemberus-gaap:AllOtherSegmentsMember2020-07-012020-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2020-07-012020-12-310001834376us-gaap:OperatingSegmentsMemberinnv:CapitationRevenueMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2020-07-012020-12-310001834376us-gaap:OperatingSegmentsMemberinnv:OtherServiceRevenueMember2020-07-012020-12-310001834376us-gaap:OperatingSegmentsMemberinnv:CapitationRevenueMember2020-07-012020-12-310001834376innv:OtherServiceRevenueMember2020-07-012020-12-310001834376innv:CapitationRevenueMember2020-07-012020-12-3100018343762021-09-300001834376srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-07-012021-12-310001834376srt:MinimumMemberinnv:EquipmentAndVehiclesMember2021-07-012021-12-310001834376srt:MinimumMemberinnv:BuildingAndLeaseholdImprovementsMember2021-07-012021-12-310001834376srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-07-012021-12-310001834376srt:MaximumMemberinnv:EquipmentAndVehiclesMember2021-07-012021-12-310001834376srt:MaximumMemberinnv:BuildingAndLeaseholdImprovementsMember2021-07-012021-12-310001834376us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001834376us-gaap:LandMember2021-12-310001834376us-gaap:ConstructionInProgressMember2021-12-310001834376innv:EquipmentAndVehiclesMember2021-12-310001834376innv:BuildingAndLeaseholdImprovementsMember2021-12-310001834376us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-06-300001834376us-gaap:LandMember2021-06-300001834376us-gaap:ConstructionInProgressMember2021-06-300001834376innv:EquipmentAndVehiclesMember2021-06-300001834376innv:BuildingAndLeaseholdImprovementsMember2021-06-300001834376us-gaap:RetainedEarningsMember2020-10-012020-12-310001834376us-gaap:NoncontrollingInterestMember2020-10-012020-12-310001834376us-gaap:NoncontrollingInterestMember2020-07-012020-12-310001834376us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-01-012021-03-310001834376us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberinnv:EskatonMember2019-03-182019-03-180001834376us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberinnv:AdventistHealthSystemWestJointVentureMember2019-03-182019-03-180001834376innv:JetdocInc.Member2021-08-012021-08-310001834376us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-12-310001834376us-gaap:NoncontrollingInterestMember2021-10-012021-12-310001834376us-gaap:NoncontrollingInterestMember2021-07-012021-12-310001834376innv:InnovageSacramentoMember2020-07-012020-12-310001834376srt:ScenarioPreviouslyReportedMember2021-06-300001834376srt:RestatementAdjustmentMember2021-06-300001834376us-gaap:ServiceOtherMember2021-12-310001834376us-gaap:ServiceOtherMember2021-06-300001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2021CreditFacilityMember2021-03-082021-03-080001834376us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberinnv:InnovageSacramentoMemberinnv:EskatonMember2019-03-182019-03-180001834376us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberinnv:InnovageSacramentoMemberinnv:AdventistHealthSystemWestJointVentureMember2019-03-182019-03-180001834376innv:InnovageSacramentoMember2019-03-182019-03-180001834376innv:InnovageSacramentoMember2021-07-012021-12-310001834376us-gaap:OtherOperatingIncomeExpenseMember2020-07-012020-12-3100018343762021-02-092021-02-090001834376us-gaap:PerformanceSharesMember2021-12-310001834376innv:TimeVestingAwardsMember2021-12-310001834376innv:TimeBasedRestrictedStockUnitsMemberinnv:OmnibusIncentivePlan2021Member2021-12-310001834376innv:TimeVestingUnitsProfitInterestsMember2021-12-310001834376innv:ProfitsInterestsUnitsMember2021-12-310001834376innv:PerformanceVestingUnitsProfitInterestsMember2021-12-310001834376innv:PerformanceBasedRestrictedStockUnitsMember2021-12-310001834376innv:TimeBasedRestrictedStockUnitsMemberinnv:OmnibusIncentivePlan2021Member2021-07-012021-12-310001834376us-gaap:PerformanceSharesMember2021-07-012021-12-310001834376innv:TimeVestingUnitsProfitInterestsMember2021-07-012021-12-310001834376us-gaap:ConvertibleDebtMember2015-09-012015-09-010001834376innv:CreditAgreement2021CreditFacilityMemberus-gaap:SeniorLoansMember2021-12-310001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2021CreditFacilityMember2021-03-080001834376innv:CreditAgreement2021CreditFacilityMemberus-gaap:SeniorLoansMember2021-03-080001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2016CreditFacilityMember2020-07-270001834376innv:CreditAgreement2016CreditFacilityMemberus-gaap:SeniorLoansMember2020-07-270001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2016CreditFacilityMember2019-05-020001834376innv:CreditAgreement2016CreditFacilityMemberus-gaap:SeniorLoansMember2019-05-020001834376innv:CreditAgreement2016CreditFacilityMemberinnv:DelayedDrawTermLoanFacilityMember2019-05-020001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2016CreditFacilityMember2016-05-130001834376innv:CreditAgreement2016CreditFacilityMemberus-gaap:SeniorLoansMember2016-05-130001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2021CreditFacilityMember2021-12-310001834376us-gaap:SeniorLoansMember2021-12-310001834376us-gaap:ConvertibleDebtMember2021-12-310001834376us-gaap:SeniorLoansMember2021-06-300001834376us-gaap:ConvertibleDebtMember2021-06-300001834376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-07-012020-12-310001834376innv:PrivatePayAndOtherCustomerMembersrt:MaximumMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:SeniorHousingMemberinnv:OtherServiceRevenueMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:PrivatePayAndOtherCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicarePartDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicarePartDMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicareCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicareCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicaidCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:MedicaidCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-12-310001834376innv:PrivatePayAndOtherCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-07-012021-06-300001834376innv:MedicareCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-07-012021-06-300001834376innv:MedicaidCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-07-012021-06-300001834376us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-07-012021-06-300001834376innv:PrivatePayAndOtherCustomerMembersrt:MaximumMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:SeniorHousingMemberinnv:OtherServiceRevenueMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:PrivatePayAndOtherCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:MedicarePartDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:MedicarePartDMemberus-gaap:CostOfGoodsProductLineMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:MedicareCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:MedicaidCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-12-310001834376innv:AdventistHealthSystemWestJointVentureMember2019-03-1800018343762020-12-3100018343762020-06-3000018343762019-03-180001834376srt:MaximumMemberinnv:NewcourtlandLifeProgramMember2018-08-0700018343762018-08-070001834376innv:NewcourtlandLifeProgramMember2018-08-072018-08-070001834376innv:InnovageSacramentoMember2021-03-310001834376innv:InnovageSacramentoMember2021-02-090001834376us-gaap:RevolvingCreditFacilityMemberinnv:CreditAgreement2021CreditFacilityMember2021-07-012021-12-310001834376innv:CreditAgreement2016CreditFacilityMember2020-07-012020-12-310001834376us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-12-310001834376us-gaap:EmployeeStockOptionMember2021-07-012021-12-310001834376innv:ProfitsInterestsUnitsMember2021-07-012021-12-310001834376us-gaap:EmployeeStockOptionMember2020-07-012020-12-310001834376innv:ProfitsInterestsUnitsMember2020-07-012020-12-310001834376us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310001834376us-gaap:AdditionalPaidInCapitalMember2021-07-012021-12-310001834376innv:OptionCancelationAgreementMember2020-07-270001834376innv:EquipmentUnderCapitalLeaseMember2021-12-310001834376innv:EquipmentUnderCapitalLeaseMember2021-06-300001834376innv:TimeVestingAwardsMember2021-07-012021-12-310001834376innv:PerformanceBasedRestrictedStockUnitsMember2021-07-012021-12-3100018343762020-07-012021-06-3000018343762019-07-012020-06-300001834376innv:AdventistHealthSystemWestJointVentureMember2019-03-182019-03-180001834376innv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2021-07-012021-12-310001834376us-gaap:RevolvingCreditFacilityMember2021-12-3100018343762021-01-012021-03-310001834376us-gaap:OperatingSegmentsMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMember2021-07-012021-12-310001834376us-gaap:OperatingSegmentsMemberinnv:ProgramOfAllInclusiveCareForElderlyOperatingSegmentsMember2020-07-012020-12-310001834376us-gaap:OperatingSegmentsMember2020-07-012020-12-310001834376us-gaap:RetainedEarningsMember2020-07-012020-12-310001834376innv:CreditAgreement2021CreditFacilityMemberus-gaap:SeniorLoansMember2021-03-082021-03-080001834376innv:CreditAgreement2016CreditFacilityMember2021-12-310001834376innv:CreditAgreement2016CreditFacilityMemberinnv:DelayedDrawTermLoanFacilityMember2020-07-272020-07-270001834376innv:JetdocInc.Member2021-08-3100018343762021-06-300001834376innv:DispatchhealthHoldingsIncMember2019-12-310001834376innv:AdventistHealthSystemWestJointVentureMember2021-02-092021-02-0900018343762021-12-3100018343762021-03-082021-03-080001834376us-gaap:RetainedEarningsMember2021-10-012021-12-3100018343762021-10-012021-12-310001834376us-gaap:RetainedEarningsMember2021-07-012021-12-310001834376us-gaap:AdditionalPaidInCapitalMember2020-10-012020-12-3100018343762020-10-012020-12-310001834376us-gaap:AdditionalPaidInCapitalMember2020-07-012020-12-3100018343762020-07-012020-12-3100018343762022-02-0800018343762021-07-012021-12-31xbrli:sharesiso4217:USDxbrli:pureinnv:Centerinnv:divisioninnv:itemiso4217:USDxbrli:sharesinnv:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from to  

Commission File Number: 001-40159

Graphic

InnovAge Holding Corp.

(Exact name of registrant as specified in its charter)

Delaware

81-0710819

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification Number)

8950 E. Lowry Boulevard

Denver, CO

(Address of Principal Executive Offices)

80230

(Zip Code)

(844) 803-8745

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

INNV

The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

As of February 8, 2022, there were 135,516,513 of the registrant’s common stock outstanding.

Table of Contents

TABLE OF CONTENTS

Page

Part I

Financial Information

Item 1.

Financial Statements (Unaudited)

5

Condensed Consolidated Balance Sheets as of December 31, 2021 (Unaudited) and June 30, 2021

5

Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2021 and 2020 (Unaudited)

6

Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended December 31, 2021 and 2020 (Unaudited)

7

Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2021 and 2020 (Unaudited)

9

Notes to Condensed Consolidated Financial Statements as of December 31, 2021 (Unaudited)

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

44

Item 4.

Controls and Procedures

44

Part II

Other Information

44

Item 1.

Legal Proceedings

44

Item 1A.

Risk Factors

45

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

48

Item 3.

Defaults Upon Senior Securities

49

Item 4.

Mine Safety Disclosures

49

Item 5.

Other Information

49

Item 6.

Exhibits

49

Exhibit Index

50

Signatures

51

2

Table of Contents

InnovAge Holding Corp. and Subsidiaries

Quarterly Report on Form 10-Q

For the quarterly period ended December 31, 2021

Cautionary Note on Forward-Looking Statements

Throughout this Quarterly Report on Form 10-Q, we make “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results or strategies and can often be identified by the use of terminology such as “may,” “will,” “estimate,” “intend,” “plan,” “continue,” “believe,” “expect,” “anticipate,” “target,” “should,” “could,” “potential,” “opportunity,” “goal” or similar terminology. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts and may include statements about our expectations to increase the number of participants we serve, to grow enrollment and capacity within existing centers, to build de novo centers, and other similar statements. The forward-looking statements contained in this Quarterly Report on Form 10-Q are generally located in the material set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in Part I, Item 2, and “Risk Factors,” included in Part II, Item 1A, but may be found in other locations as well. These statements are based upon management’s current expectations, assumptions and estimates and are not guarantees of timing, future results or performance. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. Actual results may differ materially from those contemplated in these statements due to a variety of risks and uncertainties and other factors, including, among other things:

the results of periodic inspections, reviews and audits under the federal and state government programs, including the ongoing audit of our Albuquerque, New Mexico center, the sanctions currently in place on our centers in Colorado and in our Sacramento center in California and our ability to sufficiently cure any deficiencies identified by the respective federal and state government programs;
the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;
our ability to develop and maintain proper and effective internal control over financial reporting;
the impact on our business of disruptions in our disaster recovery systems or management continuity planning;
the impact of any restrictions on our use of or ability to license data or our failure to license data and integrate third-party technologies;
our ability to attract and retain highly qualified personnel;
our management team’s limited experience managing a public company and recent Chief Executive Officer succession;
the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;
the impact of failures by our suppliers, material price increases on supplies, lack of reimbursement for drugs we purchase or limitations on our ability to access new technology or products;
our ability to maintain our corporate culture;
the impact of competition for physicians and nurses, shortages of qualified personnel and related increases in our labor costs;
our ability to attract and retain the services of key primary care physicians;
the risk that our submissions to health plans may contain inaccurate or unsupportable information regarding risk adjustment scores of members;
our ability to accurately estimate incurred but not reported medical expense;
the impact of negative publicity regarding the managed healthcare industry;
the impact of state and federal efforts to reduce Medicaid spending;
the impact on our centers of adverse weather conditions and other factors beyond our control; and
other factors disclosed in the section entitled “Risk Factors” in our Annual Report for the year ended June 30, 2021 filed with the Securities and Exchange Commission (the “SEC”) on September 22, 2021 as well as in this Quarterly Report on Form 10-Q.

3

Table of Contents

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements as well as other cautionary statements that are made from time to time in our other public communications and filings with the SEC. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Unless otherwise specified or unless the context requires otherwise, all references in this Quarterly Report on Form 10-Q to “InnovAge,” “the Company,” “we,” “us,” and “our,” or similar references, refer to InnovAge Holding Corp. and our consolidated subsidiaries.

4

Table of Contents

PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except per share data)

(Unaudited)

    

December 31, 

    

June 30, 

2021

2021

Assets

Current Assets

 

  

 

  

Cash and cash equivalents

$

216,314

$

201,466

Restricted cash

 

2,234

 

2,234

Accounts receivable, net of allowance ($2,861 – December 31, 2021 and $4,350 – June 30, 2021)

 

33,288

 

32,582

Prepaid expenses and other

 

9,458

 

9,249

Income tax receivable

 

4,644

 

5,401

Total current assets

 

265,938

 

250,932

Noncurrent Assets

 

  

 

  

Property and equipment, net

 

152,200

 

142,715

Investments

 

5,493

 

3,493

Deposits and other

 

3,966

 

3,877

Goodwill

 

124,217

 

124,217

Intangible assets, net

 

6,187

 

6,518

Total noncurrent assets

 

292,063

 

280,820

Total assets

$

558,001

$

531,752

Liabilities and Stockholders' Equity

 

  

 

  

Current Liabilities

 

  

 

  

Accounts payable and accrued expenses

$

39,223

$

32,361

Reported and estimated claims

 

34,607

 

33,234

Due to Medicaid and Medicare

8,840

7,101

Current portion of long-term debt

 

3,792

 

3,790

Current portion of capital lease obligations

 

2,854

 

2,079

Total current liabilities

 

89,316

 

78,565

Noncurrent Liabilities

 

  

 

  

Deferred tax liability, net

 

19,080

 

15,700

Capital lease obligations

 

8,788

 

5,190

Other noncurrent liabilities

 

2,489

 

2,758

Long-term debt, net of debt issuance costs

 

69,892

 

71,574

Total liabilities

 

189,565

 

173,787

Commitments and Contingencies (See Note 9)

 

  

 

  

Redeemable Noncontrolling Interests (See Note 4)

18,850

16,986

Stockholders’ Equity

 

  

 

  

Common stock, $0.001 par value; 500,000,000 authorized as of December 31, 2021 and June 30, 2021; 135,516,513 shares issued and outstanding as of both December 31, 2021 and June 30, 2021

 

136

 

136

Additional paid-in capital

 

325,501

 

323,760

Retained earnings

 

17,695

 

10,663

Total InnovAge Holding Corp.

 

343,332

 

334,559

Noncontrolling interests

 

6,254

 

6,420

Total stockholders’ equity

 

349,586

 

340,979

Total liabilities and stockholders’ equity

$

558,001

$

531,752

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except number of shares and per share data)

(Unaudited)

Three Months Ended December 31, 

Six Months Ended December 31, 

2021

    

2020

2021

    

2020

Revenues

  

 

  

  

 

  

 

Capitation revenue

$

174,964

$

156,515

$

347,518

$

308,459

Other service revenue

 

386

 

796

 

902

 

1,418

Total revenues

 

175,350

 

157,311

 

348,420

 

309,877

Expenses

 

  

 

  

 

  

 

  

External provider costs

 

91,033

 

75,145

 

181,045

 

148,826

Cost of care, excluding depreciation and amortization

 

42,911

 

38,074

 

83,639

 

76,357

Sales and marketing

 

6,679

 

4,631

 

12,972

 

8,743

Corporate, general and administrative

 

28,482

 

15,729

 

49,566

 

87,306

Depreciation and amortization

 

3,292

 

2,992

 

6,585

 

5,951

Equity loss

 

 

541

 

 

1,342

Other operating income

 

 

(343)

 

 

(1,011)

Total expenses

 

172,397

 

136,769

 

333,807

 

327,514

Operating Income (Loss)

 

2,953

 

20,542

 

14,613

 

(17,637)

Other Income (Expense)

 

  

 

  

 

  

 

  

Interest expense, net

 

(674)

 

(6,555)

 

(1,221)

 

(12,186)

Loss on extinguishment of debt

 

 

(991)

Other income (expense)

 

28

 

106

 

(465)

 

44

Total other expense

 

(646)

 

(6,449)

 

(1,686)

 

(13,133)

Income (Loss) Before Income Taxes

 

2,307

 

14,093

 

12,927

 

(30,770)

Provision for Income Taxes

 

1,201

 

4,486

 

4,197

 

9,423

Net Income (Loss)

 

1,106

 

9,607

 

8,730

 

(40,193)

Less: net loss attributable to noncontrolling interests

 

(217)

 

(98)

 

(279)

 

(243)

Net Income (Loss) Attributable to InnovAge Holding Corp.

$

1,323

$

9,705

$

9,009

$

(39,950)

Weighted-average number of common shares outstanding - basic

 

135,516,513

 

116,520,612

 

135,516,513

 

118,795,021

Weighted-average number of common shares outstanding - diluted

 

135,516,513

 

116,520,612

 

135,516,513

 

118,795,021

Net income (loss) per share - basic

$

0.01

$

0.08

$

0.07

$

(0.34)

Net income (loss) per share - diluted

$

0.01

$

0.08

$

0.07

$

(0.34)

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Table of Contents

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except per share data)

(Unaudited)

For the Three Months Ended December 31, 2021

    

    

    

    

    

    

    

    

Total

    

Redeemable

    

Additional

Retained

Permanent

Noncontrolling

Capital Stock

Paid-in

Earnings

Treasury Stock

Noncontrolling

Stockholders'

Interests

Shares

Amount

Capital

(Deficit)

Shares

Amount

Interests

Equity

(Temporary Equity)

Net Income (Loss)

Balances, September 30, 2021

 

135,516,513

 

136

 

324,718

 

18,936

 

-

 

-

 

6,326

 

350,116

 

16,431

 

Stock-based compensation

-

-

783

-

-

-

-

783

-

Net income (loss)

-

-

-

1,323

-

-

(72)

1,251

(145)

Adjustment to redemption value

 

-

 

-

 

-

 

(2,564)

 

-

 

-

 

-

 

(2,564)

 

2,564

$

-

Balances, December 31, 2021

 

135,516,513

$

136

$

325,501

$

17,695

 

-

$

-

$

6,254

$

349,586

$

18,850

For the Six Months Ended December 31, 2021

Total

    

Redeemable

Additional

Retained

Permanent

Noncontrolling

Capital Stock

Paid-in

Earnings

Treasury Stock

Noncontrolling

Stockholders'

Interests

Shares

Amount

Capital

(Deficit)

Shares

Amount

Interests

Equity

(Temporary Equity)

Net Income (Loss)

Balances, June 30, 2021

 

135,516,513

 

136

 

323,760

 

10,663

 

-

 

-

 

6,420

 

340,979

 

16,986

 

Stock-based compensation

-

-

1,741

-

-

-

-

1,741

-

Net income (loss)

-

-

-

9,009

(166)

8,843

(113)

Adjustment to redemption value

 

-

 

-

 

-

 

(1,977)

 

-

 

-

 

-

 

(1,977)

 

1,977

$

-

Balances, December 31, 2021

 

135,516,513

$

136

$

325,501

$

17,695

 

-

$

-

$

6,254

$

349,586

$

18,850

7

Table of Contents

    

For the Three Months Ended December 31, 2020

  

  

Additional

  

  

  

  

  

Capital Stock

Paid-in

Retained

Treasury Stock

Noncontrolling

    

Shares

    

Amount

    

Capital

    

Earnings

    

Shares

    

Amount

    

Interests

    

Total

Balances, September 30, 2020

 

132,718,461

$

133

$

4,026

$

5,626

 

16,197,849

$

(77,796)

$

6,589

$

(61,422)

Stock-based compensation

 

 

 

526

 

 

 

 

 

526

Owner contribution

 

 

 

20,000

 

 

 

 

 

20,000

Net income (loss)

 

 

 

 

9,705

 

 

 

(98)

 

9,607

Balances, December 31, 2020

 

132,718,461

$

133

$

24,552

$

15,330

 

16,197,849

$

(77,796)

$

6,492

$

(31,289)

    

For the Six Months Ended December 31, 2020

  

  

Additional

  

  

  

  

  

Capital Stock

Paid-in

Retained

Treasury Stock

Noncontrolling

    

Shares

    

Amount

    

Capital

    

Earnings

    

Shares

    

Amount

    

Interests

    

Total

Balances, June 30, 2020

 

132,718,461

$

133

$

36,338

$

64,737

 

102,030

$

(193)

$

6,735

$

107,750

Treasury stock transaction

 

 

 

 

 

16,095,819

 

(77,603)

 

 

(77,603)

Owner distribution

 

 

 

 

(9,457)

 

 

 

 

(9,457)

Time based awards- option cancelation

 

 

 

(32,358)

 

 

 

 

 

(32,358)

Stock-based compensation

 

 

 

572

 

 

 

 

 

572

Owner contribution

 

 

 

20,000

 

 

 

 

 

20,000

Net income (loss)

 

 

 

 

(39,950)

 

 

 

(243)

 

(40,193)

Balances, December 31, 2020

 

132,718,461

$

133

$

24,552

$

15,330

 

16,197,849

$

(77,796)

$

6,492

$

(31,289)

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Table of Contents

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

For the Six Months Ended December 31, 

2021

2020

Operating Activities

Net income (loss)

$

8,730

$

(40,193)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities

 

 

  

Loss on disposal of assets

 

465

 

Provision for uncollectible accounts

 

2,883

 

2,712

Depreciation and amortization

 

6,585

 

5,951

Loss on extinguishment of long-term debt

 

 

991

Amortization of deferred financing costs

 

215

 

652

Stock-based compensation

 

1,741

 

572

Deferred income taxes

 

3,380

 

6,084

Loss in equity of nonconsolidated entities

 

 

1,342

Change in fair value of contingent consideration

(1,011)

Changes in operating assets and liabilities, net of acquisitions

 

  

 

  

Accounts receivable, net

 

(3,589)

 

4,171

Prepaid expenses and other

 

(209)

 

(385)

Income tax receivable

 

757

 

1,738

Deposits and other

 

(89)

 

(315)

Accounts payable and accrued expenses

 

7,596

 

2,351

Reported and estimated claims

 

1,373

 

6,204

Due to Medicaid and Medicare

 

1,739

 

8,393

Net cash provided by (used in) operating activities

 

31,577

 

(743)

Investing Activities

 

  

 

  

Purchases of property and equipment

 

(11,681)

 

(11,464)

Purchase of intangible assets

 

 

(2,000)

Purchase of cost method investment

 

(2,000)

 

Net cash used in investing activities

$

(13,681)

$

(13,464)

Financing Activities

 

Distributions to owners

$

$

(9,457)

Owner contributions

 

 

20,000

Payments on capital lease obligations

 

(1,154)

 

(1,079)

Proceeds from long-term debt

300,000

Principal payments on long-term debt

 

(1,894)

 

(213,390)

Payment of financing costs and debt premiums

 

 

(7,478)

Treasury stock purchases

 

 

(77,603)

Payments related to option cancellation

(32,358)

Net cash used in financing activities

 

(3,048)

 

(21,365)

INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH

 

14,848

 

(35,572)

CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD

 

203,700

 

114,565

CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD

$

218,548

$

78,993

Supplemental Cash Flows Information

 

  

 

  

Interest paid

$

984

$

8,154

Income taxes paid

$

84

$

1,638

Property and equipment included in accounts payable

$

1,004

$

217

Property and equipment purchased under capital leases

$

5,653

$

3,527

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

Table of Contents

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1:Business

InnovAge Holding Corp. (formerly, TCO Group Holdings, Inc.) was formed May 13, 2016, to acquire the business of Total Community Options, Inc. d/b/a InnovAge, which was formed in May 2007. In connection with the Company’s initial public offering (“IPO”), which occurred in March 2021, we changed the name of our Company from TCO Group Holdings, Inc. to InnovAge Holding Corp.

InnovAge Holding Corp. and its subsidiaries, which are headquartered in Denver, Colorado have a record of innovation, quality, and sensitivity to the needs of participants and staff. The Company manages, and in many cases directly provides, a broad range of medical and ancillary services for seniors in need of care and support to safely live independently in their homes and communities, including in-home care services (skilled, unskilled and personal care); in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the Program of All-Inclusive Care for the Elderly (“PACE”) center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE.

As of December 31, 2021, the Company served approximately 7,050 PACE participants, making it the largest PACE provider in the United States of America (the “U.S.”) based upon participants served, and operates 18 PACE centers across Colorado, California, New Mexico, Pennsylvania and Virginia.

PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. InnovAge is obligated to provide and participants receive all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans Administration (“VA”), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services (“CMS”) share part of the risk for providing prescription medication to the Company’s participants.

On March 8, 2021, we completed our IPO. The Company’s common stock began trading on the Nasdaq Stock Market LLC (“NASDAQ”) under the ticker symbol “INNV”.

Note 2:Summary of Significant Accounting Policies

The Company described its significant accounting policies in Note 2, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in its Annual Report on Form 10-K for the year ended June 30, 2021 (“2021 10-K”). During the six months ended December 31, 2021, there were no significant changes to those accounting policies.

Basis of Preparation and Principles of Consolidation

The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended June 30, 2021. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. The condensed consolidated financial statements include the accounts of InnovAge, its wholly owned subsidiaries, variable interest entities (“VIEs”)

10

Table of Contents

for which it is the primary beneficiary and entities for which it has a controlling interest. All intercompany accounts and transactions have been eliminated in consolidation.

The Company does not have any components of comprehensive income and comprehensive income is equal to net income reported in the statements of operations for all periods presented.

Restatement of Prior Period Financial Statements

Subsequent to the issuance of the Company’s condensed consolidated financial statements as of and for the year ended June 30, 2021, we identified an error in our consolidated balance sheet and statement of stockholders’ equity as of June 30, 2021 related to the presentation of redeemable noncontrolling interests. The Company incorrectly recorded redeemable noncontrolling interests of $17.0 million as permanent equity rather than temporary equity as of June 30, 2021.  As a result, the Company restated the June 30, 2021 condensed consolidated financial statements to reflect this reclassification from permanent to temporary equity and to record the related adjustment to redemption value as of June 30, 2021. Management evaluated the materiality of this misstatement and concluded that it is not material to the prior period. The effect of the restatement on the consolidated balance sheet as of June 30, 2021 is as follows (in thousands):

As Previously

    

Reported

    

Adjustments

    

As Restated

Redeemable Noncontrolling Interests (See Note 4)

 

 

16,986

 

16,986

Retained earnings

 

11,250

 

(587)

 

10,663

Total InnovAge Holding Corp.

 

335,146

 

(587)

 

334,559

Noncontrolling interests

 

22,819

 

(16,399)

 

6,420

Total stockholders’ equity

 

357,965

 

(16,986)

 

340,979

The effect of the restatement on the balances as of June 30, 2021 included in the consolidated statement of stockholders’ equity as of December 31, 2021 is as follows (in thousands):

Redeemable

Total Permanent

Noncontrolling

Retained

Noncontrolling

Stockholders’

Interests

    

Earnings

    

Interests

    

Equity

    

(Temporary Equity)

As Previously Reported

 

  

 

  

 

  

 

  

Balances, June 30, 2021

 

11,250

 

22,819

 

357,965

 

Adjustments

 

  

 

  

 

  

 

  

Balances, June 30, 2021

 

(587)

 

(16,399)

 

(16,986)

 

16,986

As Restated

 

  

 

  

 

  

 

  

Balances, June 30, 2021

 

10,663

 

6,420

 

340,979

 

16,986

Property and Equipment

Property and equipment were comprised of the following as of December 31, 2021 and June 30, 2021:

    

Estimated

    

    

dollars in thousands

Useful Lives

December 31, 2021

June 30, 2021

Land

 

N/A

$

11,980

$

11,980

Buildings and leasehold improvements

 

10 - 40 years

 

121,644

 

104,724

Software

 

3 - 5 years

 

13,964

 

13,316

Equipment and vehicles

 

3 - 7 years

 

43,006

 

35,341

Construction in progress

 

N/A

 

12,164

 

22,130

 

 

202,758

187,491

Less accumulated depreciation and amortization

 

 

(50,558)

 

(44,776)

Total property and equipment, net

$

152,200

$

142,715

11

Table of Contents

Depreciation of $6.1 million and $5.6 million was recorded during the six months ended December 31, 2021 and 2020, respectively.

Coronavirus Pandemic (“COVID-19”)

In March 2020, the World Health Organization declared COVID-19 a pandemic. The global spread of COVID-19 has created significant volatility, uncertainty, and economic disruption. Governments in affected regions have implemented, and may continue to implement, safety precautions which include quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures as they deem necessary. Many organizations and individuals, including the Company and its employees, continue to take additional steps to avoid or reduce infection, including limiting travel and working from home. These measures are disrupting normal business operations both in and outside of affected areas and have had significant negative impacts on businesses worldwide. As a PACE organization, we have been and will continue to be impacted by the effects of COVID-19. We closed all our centers in March 2020 and transitioned to a 100% in-home and virtual care model. We believe that the general lack of in-person interaction and the reduction in healthcare personnel, and specifically, trained personnel, impacted our ability to adhere to the complex government laws and regulations that apply to our business. We remain committed to carrying out our mission of caring for our participants. We continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, participants and suppliers. Due to the numerous evolving factors, we are unable to reliably estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into legislation. The CARES Act provided for $100.0 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Under the CARES Act, the state of Pennsylvania signed into law the Act 24 of 2020, which allocated $10.0 million of funding from the federal CARES Act to managed long term care organizations. Funding from the Act 24 of 2020 was to be used to cover necessary COVID-19 related costs incurred between March 1, 2020 and November 30, 2020 for entities in operation as of March 31, 2020. We received $1.0 million in funding under the Act 24 of 2020, which was allocated to InnovAge centers in Pennsylvania. Of the $1.0 million, $0.7 million was recognized prior June 30, 2020 and the remaining balance of $0.3 million was recognized during the year ended June 30, 2021. The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period of May 1, 2020 through December 31, 2020. The Consolidated Appropriations Act, 2021, enacted December 27, 2020, extended this suspension for three more months, through March 31, 2021.  H.R. 1868, enacted on April14, 2021 further extends the suspension through December 31, 2021. On December 10, 2021 the “Protecting Medicare and American Farmers from Sequester Cuts Act” extends the 2% Medicare sequester moratorium through March 31, 2022, and adjusts the sequester to 1% between April 1, 2022 and June 30, 2022.

Recently Adopted Accounting Pronouncements

Income Taxes

In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes Topic 740-Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of Topic 740. This guidance is effective for companies with fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company adopted ASU 2019-12 during the quarter ended September 30, 2021 and it did not have a material effect on the Company’s condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

Leases

In February 2016, the FASB issued ASU 2016-02 Leases (“ASU 2016-02”), which was intended to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and

12

Table of Contents

disclosing key information about leasing arrangements. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than 12 months. Additionally, this guidance will require disclosures to help investors and other financial statement users to better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. The guidance should be applied under a modified retrospective transition approach for leases existing at the beginning of the earliest comparative period presented in the adoption-period financial statements. Any leases that expire before the initial application date will not require any accounting adjustment. In June 2020, FASB issued ASU 2020-05 Revenue from contracts with customers (Topic 606) and leases (Topic 842)—Effective dates for certain entities which deferred the new lease standard effective date for the Company to December 15, 2022, with early adoption permitted. The Company will adopt this ASU in the fiscal year beginning July 1, 2022 and has not yet determined the effect of the standard on its ongoing financial reporting.

Financial Instruments

In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (“ASU 2019-04”), which requires entities to use a current expected credit loss (“CECL”) model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. This guidance also expands the required credit loss disclosures and will be applied using a modified retrospective approach by recording a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. ASU 2019-04 is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt this guidance for the annual and interim reporting periods beginning July 1, 2023. The Company has not determined the effect of the standard on its condensed consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our condensed consolidated financial statements.

Note 3:Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation.

Capitation Revenue and Accounts Receivable

Our capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a per member, per month (“PMPM”) basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants.

Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE

13

Table of Contents

program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company provides comprehensive care to its participants.

Our revenues are based on the estimated PMPM  amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program.  VA is included in “Private Pay and other” and is also capitated.  Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate.

The Company disaggregates capitation revenue from the following sources for the six months ended:

    

December 31, 

    

    

2021

    

2020

    

Medicaid

 

54

%

52

%

Medicare

 

46

%

47

%

Private pay and other

 

*

%

1

%

Total

 

100

%

100

%

______________

* Less than 1%

The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustments based on various factors. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material.

The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of se